BACKGROUND: High prevalences of reduced glomerular filtration rate (GFR) have been reported from HIV-infected individuals in sub-Saharan Africa when initiating antiretroviral therapy. However little is known about natural history HIV-related kidney disease or about background rates of reduced GFR in HIV-negative individuals in this region. METHODS: We estimated GFR from first and last available stored serum samples from 1202 HIV-infected and 664 age-matched and sex-matched HIV-negative individuals in a community-based cohort of HIV-infected and HIV-negative individuals in Rakai, Uganda, between 1994 and 2003. We assessed the prevalence and incidence of mildly (60-89 ml·min·1.73 m) and moderately (<60 ml·min·1.73 m) reduced GFR using standard analytical methods. RESULTS: At baseline, 8.4% of HIV-infected and 4.7% of HIV-negative individuals had mildly or moderately reduced GFR (P = 0.002). During follow-up, the rates of decline to a lower GFR category were of 32.4 and 20.3 per 1000 person-years in HIV-infected and HIV-negative subjects, respectively (P = 0.019). CONCLUSIONS: In an unselected community sample of HIV-infected individuals followed in Rakai, Uganda, before the availability of antiretroviral therapy, the prevalence of decreased GFR and the incidence of a decline in GFR category during follow-up were both significantly higher in HIV-infected subjects compared with HIV-negative subjects, although moderately reduced GFR was uncommon.
BACKGROUND: High prevalences of reduced glomerular filtration rate (GFR) have been reported from HIV-infected individuals in sub-Saharan Africa when initiating antiretroviral therapy. However little is known about natural history HIV-related kidney disease or about background rates of reduced GFR in HIV-negative individuals in this region. METHODS: We estimated GFR from first and last available stored serum samples from 1202 HIV-infected and 664 age-matched and sex-matched HIV-negative individuals in a community-based cohort of HIV-infected and HIV-negative individuals in Rakai, Uganda, between 1994 and 2003. We assessed the prevalence and incidence of mildly (60-89 ml·min·1.73 m) and moderately (<60 ml·min·1.73 m) reduced GFR using standard analytical methods. RESULTS: At baseline, 8.4% of HIV-infected and 4.7% of HIV-negative individuals had mildly or moderately reduced GFR (P = 0.002). During follow-up, the rates of decline to a lower GFR category were of 32.4 and 20.3 per 1000 person-years in HIV-infected and HIV-negative subjects, respectively (P = 0.019). CONCLUSIONS: In an unselected community sample of HIV-infected individuals followed in Rakai, Uganda, before the availability of antiretroviral therapy, the prevalence of decreased GFR and the incidence of a decline in GFR category during follow-up were both significantly higher in HIV-infected subjects compared with HIV-negative subjects, although moderately reduced GFR was uncommon.
Authors: Michelle E Tarver-Carr; Neil R Powe; Mark S Eberhardt; Thomas A LaVeist; Raynard S Kington; Josef Coresh; Frederick L Brancati Journal: J Am Soc Nephrol Date: 2002-09 Impact factor: 10.121
Authors: Jeffrey B Kopp; Michael W Smith; George W Nelson; Randall C Johnson; Barry I Freedman; Donald W Bowden; Taras Oleksyk; Louise M McKenzie; Hiroshi Kajiyama; Tejinder S Ahuja; Jeffrey S Berns; William Briggs; Monique E Cho; Richard A Dart; Paul L Kimmel; Stephen M Korbet; Donna M Michel; Michele H Mokrzycki; Jeffrey R Schelling; Eric Simon; Howard Trachtman; David Vlahov; Cheryl A Winkler Journal: Nat Genet Date: 2008-09-14 Impact factor: 38.330
Authors: Gregory M Lucas; Bryan Lau; Mohamed G Atta; Derek M Fine; Jeanne Keruly; Richard D Moore Journal: J Infect Dis Date: 2008-06-01 Impact factor: 5.226
Authors: Philip J Peters; David M Moore; Jonathan Mermin; John T Brooks; Robert Downing; Willy Were; Aminah Kigozi; Kate Buchacz; Paul J Weidle Journal: Kidney Int Date: 2008-07-09 Impact factor: 10.612
Authors: Kara Wools-Kaloustian; Samir K Gupta; Eva Muloma; Willis Owino-Ong'or; John Sidle; Ryan W Aubrey; Jianzhao Shen; Kirwa Kipruto; Beth E Zwickl; Mitchell Goldman Journal: Nephrol Dial Transplant Date: 2007-08 Impact factor: 5.992
Authors: Lloyd B Mulenga; Gina Kruse; Shabir Lakhi; Ronald A Cantrell; Stewart E Reid; Isaac Zulu; Elizabeth M Stringer; Zipporah Krishnasami; Alwyn Mwinga; Michael S Saag; Jeffrey S A Stringer; Benjamin H Chi Journal: AIDS Date: 2008-09-12 Impact factor: 4.177
Authors: Amanda Mocroft; Ole Kirk; Jose Gatell; Peter Reiss; Panagiotis Gargalianos; Kai Zilmer; Marek Beniowski; Jean-Paul Viard; Schlomo Staszewski; Jens D Lundgren Journal: AIDS Date: 2007-05-31 Impact factor: 4.177
Authors: Wolfgang Stöhr; A Sarah Walker; Paula Munderi; Stefano Tugume; Charles F Gilks; Janet H Darbyshire; James Hakim Journal: Antivir Ther Date: 2008
Authors: Julie A Ake; Christina S Polyak; Trevor A Crowell; Francis Kiweewa; Michael Semwogerere; Lucas Maganga; Emmanuel Bahemana; Jonah Maswai; Rither Langat; John Owuoth; Solomon Otieno; Babajide Keshinro; Allahna L Esber; Michelle Liu; Leigh Anne Eller; Kavitha Ganesan; Ajay P Parikh; Tiffany E Hamm; Merlin L Robb; Patrick W Hickey; Victor G Valcour; Nelson L Michael Journal: Clin Infect Dis Date: 2019-08-01 Impact factor: 9.079
Authors: Natalia Papeta; Roel Sterken; Krzysztof Kiryluk; Robert Kalyesubula; Ali G Gharavi Journal: J Mol Med (Berl) Date: 2011-01-11 Impact factor: 4.599
Authors: Fowzia Ibrahim; Lisa Hamzah; Rachael Jones; Dorothea Nitsch; Caroline Sabin; Frank A Post Journal: Am J Kidney Dis Date: 2012-04-21 Impact factor: 8.860
Authors: Christina M Wyatt; Qiuhu Shi; James E Novak; Donald R Hoover; Lynda Szczech; Jules Semahore Mugabo; Agnes Binagwaho; Mardge Cohen; Eugene Mutimura; Kathryn Anastos Journal: PLoS One Date: 2011-03-28 Impact factor: 3.240
Authors: G Emerens Wensink; Annelot F Schoffelen; Hugo A Tempelman; Maarten B Rookmaaker; Andy I M Hoepelman; Roos E Barth Journal: PLoS One Date: 2015-08-26 Impact factor: 3.240